☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New Obesity Treatment Launched

Rimonabant (Acomplia®) has been launched in the UK. It is licensed as an adjunct to diet and exercise in patients with a BMI > 30kg/m2 or a BMI > 27 kg/m2 and associated risk factors such as Type II Diabetes.

The full Summary of Product Characteristics is available online. It should be noted that this drug is black triangle and all suspected adverse reactions should be reported.

It is expected that there will be a high level of media interest, especially as this drug is a cannabinoid-1 (CB1) receptor blocker. At this time there are no comparative studies comparing this new treatment with the currently available treatment options.

The costs of the available treatments are:

  • Orlistat (Xenical®) - £39.51 per month
  • Sibutramine (Reductil®) - £41.29 to £45.14 per month
  • Rimonobant (Acomplia®) - £55.20 per month

Action: Based on the lack of comparative studies and the higher acquisition cost this drug provides a fourth-line choice in patients who fail to respond to diet and exercise followed by both existing treatment options.

Share 'New Obesity Treatment Launched' by emailShare 'New Obesity Treatment Launched' on FacebookShare 'New Obesity Treatment Launched' on TwitterShare 'New Obesity Treatment Launched' on LinkedInShare 'New Obesity Treatment Launched' on reddit


One Comment to “New Obesity Treatment Launched”

  1. […] previously discussed, rimonobant occupies a last line option for treatment of obesity as an adjunct to diet and […]

    Pingback by FDA reject rimonabant | Prescribing Advice for GPs — June 14, 2007 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.